Huntington's Disease Clinical Trial
— Open PRIDE-HDOfficial title:
A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)
Verified date | August 2021 |
Source | Prilenia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
Status | Terminated |
Enrollment | 248 |
Est. completion date | January 12, 2018 |
Est. primary completion date | January 12, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - Pride HD completion within the last 6 months, including 2 week follow up period or patients who transitioned from the Open HART study or patients who complete future safety and efficacy clinical trials of pridopidine. In addition, patients who have already completed their defined study period under Open PRIDE HD global or local amendments and have discontinued treatment with pridopidine will be allowed to re enter the Open PRIDE HD study. - Women of child bearing potential or male participants: Adequate contraception and birth control - Good general health - other criteria apply, please contact the investigator for more information Exclusion Criteria: - Similar baseline criteria for ECG, vital signs, cardiovascular system, and renal function to PRIDE HD; - Similar concomitant medication restrictions to PRIDE HD. - other criteria apply, please contact the investigator for more information |
Country | Name | City | State |
---|---|---|---|
Australia | Teva Investigational Site 78055 | Caulfield South | |
Australia | Teva Investigational Site 78058 | West Perth | |
Australia | Teva Investigational Site 78057 | Westmead | |
Austria | Teva Investigational Site 33021 | Innsbruck | |
Austria | Teva Investigational Site 33027 | Wien | |
Canada | Teva Investigational Site 11036 | Toronto | Ontario |
France | Teva Investigational Site 35123 | Angers cedex 9 | |
France | Teva Investigational Site 35122 | Creteil | |
France | Teva Investigational Site 35125 | Lille Cedex | |
France | Teva Investigational Site 35124 | Marseille Cedex 5 | |
France | Teva Investigational Site 35121 | Salouel | |
France | Teva Investigational Site 35165 | Toulouse | |
Germany | Teva Investigational Site 32408 | Berlin | |
Germany | Teva Investigational Site 32410 | Bochum | |
Germany | Teva Investigational Site 32409 | Munster | |
Germany | Teva Investigational Site 32407 | Ulm | |
Italy | Teva Investigational Site 30083 | Firenze | |
Italy | Teva Investigational Site 30080 | Milano | |
Italy | Teva Investigational Site 30082 | Napoli | |
Italy | Teva Investigational Site 30081 | San Giovanni Rotondo | |
Netherlands | Teva Investigational Site 38059 | Leiden | |
Poland | Teva Investigational Site 53150 | Gdansk | |
Poland | Teva Investigational Site 53149 | Krakow | |
Poland | Teva Investigational Site 53148 | Poznan | |
Poland | Teva Investigational Site 53151 | Warsaw | |
Russian Federation | Teva Investigational Site 50215 | Kazan | |
Russian Federation | Teva Investigational Site 50213 | Moscow | |
Russian Federation | Teva Investigational Site 50214 | Nyznij Novgorod | |
United Kingdom | Teva Investigational Site 34058 | Birmingham | |
United Kingdom | Teva Investigational Site 34054 | Cambridge | |
United Kingdom | Teva Investigational Site 34059 | Cardiff | |
United Kingdom | Teva Investigational Site 34055 | Manchester | |
United Kingdom | Teva Investigational Site 34061 | Newcastle-Upon-Tyne | |
United Kingdom | Teva Investigational Site 34056 | Oxford | |
United Kingdom | Teva Investigational Site 34057 | Sheffield | |
United States | Teva Investigational Site 12206 | Baltimore | Maryland |
United States | Teva Investigational Site 12201 | Englewood | Colorado |
United States | Teva Investigational Site 12204 | Los Angeles | California |
United States | Teva Investigational Site 12200 | Manhasset | New York |
United States | Teva Investigational Site 12203 | New York | New York |
United States | Teva Investigational Site 12209 | Pittsburgh | Pennsylvania |
United States | Teva Investigational Site 12210 | Richmond | Virginia |
United States | Teva Investigational Site 12198 | Rochester | New York |
United States | Teva Investigational Site 12208 | Salt Lake City | Utah |
United States | Teva Investigational Site 12196 | Washington | District of Columbia |
United States | Teva Investigational Site 12211 | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Prilenia |
United States, Australia, Austria, Canada, France, Germany, Italy, Netherlands, Poland, Russian Federation, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Adverse Events | From signature of the informed consent form through the end of the study, which was defined as Week 106 | 106 weeks | |
Secondary | Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Inter-Onset-interval-SD-Hand | Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Inter-Onset-interval-SD-Hand, measured in seconds. Positive change from baseline indicates worsening. | Week 52; end of treatment (EOT) which was planned to occur at Week 104 | |
Secondary | Change From Baseline in Quantitative Motor (Q-motor) Measurements, Pro-Sup-Peak-Force-CV-Hand | Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Peak-Force-CV-Hand, measured in %. Positive change from baseline indicates worsening. | Week 52; end of treatment (EOT) which was planned to occur at Week 104 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04120493 -
Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02956148 -
Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers
|
Early Phase 1 | |
Completed |
NCT02197130 -
Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease
|
Phase 2 | |
Completed |
NCT02208934 -
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers
|
Phase 1 | |
Completed |
NCT02216474 -
Brain Stimulation in Movement Disorders
|
N/A | |
Completed |
NCT01806896 -
Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease
|
Phase 2 | |
Completed |
NCT01502046 -
Neuroprotection by Cannabinoids in Huntington's Disease
|
Phase 2 | |
Terminated |
NCT00712426 -
Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)
|
Phase 3 | |
Completed |
NCT00670709 -
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
|
||
Completed |
NCT00029874 -
Minocycline in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02231580 -
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
|
Phase 2 | |
Completed |
NCT02215616 -
A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod
|
Phase 2 | |
Not yet recruiting |
NCT02551705 -
Functional Imaging of Social Cognition in Premanifest Huntington's Disease
|
N/A | |
Active, not recruiting |
NCT02101957 -
Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)
|
Phase 2/Phase 3 | |
Completed |
NCT01521832 -
Escalating Dose Study in Healthy Volunteers With SEN0014196
|
Phase 1 | |
Completed |
NCT00990613 -
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
|
Phase 1 | |
Completed |
NCT00975481 -
A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users
|
Phase 1 | |
Completed |
NCT00387270 -
Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT00095355 -
Effects of Lithium and Divalproex`on Brain-Derived Neurotrophic Factor in Huntington's Disease
|
Phase 2 | |
Completed |
NCT00026988 -
Creatine Therapy for Huntington's Disease
|
Phase 1/Phase 2 |